Ramesh K Ramanathan1, Shannon L McDonough2,3, Philip A Philip4, Sunil R Hingorani3, Jill Lacy5, Jeremy S Kortmansky5, Jaykumar Thumar5,6, E Gabriela Chiorean3,7, Anthony F Shields4, Deepti Behl8, Paul T Mehan9, Rakesh Gaur10, Tara Seery11, Katherine A Guthrie2,3, Howard S Hochster12. 1. 1 Mayo Clinic Cancer Center, Phoenix, AZ. 2. 2 Southwest Oncology Group Statistics and Data Management Center, Seattle, WA. 3. 3 Fred Hutchinson Cancer Research Center, Seattle, WA. 4. 4 Karmanos Cancer Institute/Wayne State University, Detroit, MI. 5. 5 Yale Cancer Center, New Haven, CT. 6. 6 Saint Francis Hospital and Medical Center, Enfield, MA. 7. 7 University of Washington, Seattle, WA. 8. 8 Sutter Cancer Research Consortium, Sacramento, CA. 9. 9 Heartland NCI Community Oncology Research Program (NCORP), Missouri Baptist Medical Center Cancer Center, St Louis, MO. 10. 10 Kansas City NCI Community Oncology Research Program (NCORP), Prairie Village, KS. 11. 11 UC Irvine Medical Center, Orange, CA. 12. 12 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Abstract
PURPOSE: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC). MATERIALS AND METHODS: Patients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. After a phase Ib dose-finding study of mFOLFIRINOX plus PEGPH20, the phase II open-label study randomly assigned patients (1:1) to the combination arm or to mFOLFIRINOX alone (n = 138). The primary end point was overall survival (OS). RESULTS: PEGPH20 dosages of 3 µg/kg every 2 weeks were more tolerable than twice-weekly dosages used in the phase I study, so 3 µg/kg every 2 weeks was the phase II dosage. An amendment instituted enoxaparin prophylaxis in the PEGPH20 combination arm as a result of increased thromboembolic (TE) events. The planned interim futility analysis when 35 deaths (of 103 analyzable patients) occurred resulted in an OS hazard ratio (HR) of 2.07 that favored the control arm, and the study was closed to accrual. The treatment-related grade 3 to 4 toxicity was significantly increased in the PEGPH20 combination arm relative to control (odds ratio, 2.7; 95% CI, 1.1 to 7.1). The median OS in the mFOLFIRINOX arm was 14.4 months (95% CI, 10.1 to 15.7 months) versus 7.7 months (95% CI, 4.6 to 9.3 months) in the PEGPH20 combination arm. CONCLUSION: Addition of PEGPH20 to mFOLFIRINOX seems to be detrimental in patients unselected for tumor HA status. This combination caused increased toxicity (mostly GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone. The median OS in the mFOLFIRINOX control arm (14.4 months) is, to our knowledge, the longest yet reported and can be considered for patients with good PS.
PURPOSE: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC). MATERIALS AND METHODS: Patients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. After a phase Ib dose-finding study of mFOLFIRINOX plus PEGPH20, the phase II open-label study randomly assigned patients (1:1) to the combination arm or to mFOLFIRINOX alone (n = 138). The primary end point was overall survival (OS). RESULTS: PEGPH20 dosages of 3 µg/kg every 2 weeks were more tolerable than twice-weekly dosages used in the phase I study, so 3 µg/kg every 2 weeks was the phase II dosage. An amendment instituted enoxaparin prophylaxis in the PEGPH20 combination arm as a result of increased thromboembolic (TE) events. The planned interim futility analysis when 35 deaths (of 103 analyzable patients) occurred resulted in an OS hazard ratio (HR) of 2.07 that favored the control arm, and the study was closed to accrual. The treatment-related grade 3 to 4 toxicity was significantly increased in the PEGPH20 combination arm relative to control (odds ratio, 2.7; 95% CI, 1.1 to 7.1). The median OS in the mFOLFIRINOX arm was 14.4 months (95% CI, 10.1 to 15.7 months) versus 7.7 months (95% CI, 4.6 to 9.3 months) in the PEGPH20 combination arm. CONCLUSION: Addition of PEGPH20 to mFOLFIRINOX seems to be detrimental in patients unselected for tumor HA status. This combination caused increased toxicity (mostly GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone. The median OS in the mFOLFIRINOX control arm (14.4 months) is, to our knowledge, the longest yet reported and can be considered for patients with good PS.
Authors: Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Sunil R Hingorani; Lei Zheng; Andrea J Bullock; Tara E Seery; William P Harris; Darren S Sigal; Fadi Braiteh; Paul S Ritch; Mark M Zalupski; Nathan Bahary; Paul E Oberstein; Andrea Wang-Gillam; Wilson Wu; Dimitrios Chondros; Ping Jiang; Sihem Khelifa; Jie Pu; Carrie Aldrich; Andrew E Hendifar Journal: J Clin Oncol Date: 2017-12-12 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Sunil R Hingorani; William P Harris; J Thaddeus Beck; Boris A Berdov; Stephanie A Wagner; Eduard M Pshevlotsky; Sergei A Tjulandin; Oleg A Gladkov; Randall F Holcombe; Ronald Korn; Natarajan Raghunand; Samuel Dychter; Ping Jiang; H Michael Shepard; Craig E Devoe Journal: Clin Cancer Res Date: 2016-01-26 Impact factor: 12.531
Authors: Michael A Jacobetz; Derek S Chan; Albrecht Neesse; Tashinga E Bapiro; Natalie Cook; Kristopher K Frese; Christine Feig; Tomoaki Nakagawa; Meredith E Caldwell; Heather I Zecchini; Martijn P Lolkema; Ping Jiang; Anne Kultti; Curtis B Thompson; Daniel C Maneval; Duncan I Jodrell; Gregory I Frost; H M Shepard; Jeremy N Skepper; David A Tuveson Journal: Gut Date: 2012-03-30 Impact factor: 23.059
Authors: Jeffrey R Infante; Ronald L Korn; Lee S Rosen; Patricia LoRusso; Samuel S Dychter; Joy Zhu; Daniel C Maneval; Ping Jiang; H Michael Shepard; Gregory Frost; Daniel D Von Hoff; Mitesh J Borad; Ramesh K Ramanathan Journal: Br J Cancer Date: 2017-09-26 Impact factor: 7.640
Authors: Alex B Blair; Victoria M Kim; Stephen T Muth; May Tun Saung; Nathalie Lokker; Barbara Blouw; Todd D Armstrong; Elizabeth M Jaffee; Takahiro Tsujikawa; Lisa M Coussens; Jin He; Richard A Burkhart; Christopher L Wolfgang; Lei Zheng Journal: Clin Cancer Res Date: 2019-06-11 Impact factor: 12.531
Authors: Haeseong Park; Ramon U Jin; Andrea Wang-Gillam; Rama Suresh; Caron Rigden; Manik Amin; Benjamin R Tan; Katrina S Pedersen; Kian-Huat Lim; Nikolaos A Trikalinos; Abhilasha Acharya; Megan L Copsey; Katherine A Navo; Ashley E Morton; Feng Gao; A Craig Lockhart Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777
Authors: Sriram Anbil; Michael Pigula; Huang-Chiao Huang; Srivalleesha Mallidi; Mans Broekgaarden; Yan Baglo; Pushpamali De Silva; Diane M Simeone; Mari Mino-Kenudson; Edward V Maytin; Imran Rizvi; Tayyaba Hasan Journal: Mol Cancer Ther Date: 2020-03-27 Impact factor: 6.261